AstraZeneca Invites Partners to Wuxi to Unlock Infinite Innovation Potential in Advancing the 'Healthy China 2030' Initiative

In 2025, China enters a critical year for concluding the 14th Five-Year Plan and advancing the key initiatives of the “Healthy China 2030” strategy.

Looking back over the past decade, the “Outline of the ‘Healthy China 2030’ Plan” promulgated in 2016 acted like a “butterfly flapping its wings,” transforming the strategic vision of “Healthy China” into an action agenda. It has built a full-chain policy innovation ecosystem covering R&D, approval, production, and market access, propelling China to become a global hotspot for innovation in the life and health industry.

“Healthy China 2030” has entered the final five-year sprint, drawing significant attention to its trajectory. On one hand, a tripartite integration among the state, industry, and basic research is in place, focusing squarely on original innovation in core technologies, with numerous medical achievements transitioning from laboratories to industrial application. Meanwhile, China remains steadfast in advancing high-standard opening-up and continuously optimizing the foreign investment environment. Multinational pharmaceutical and medical device giants are increasing their investments in China and deepening local collaborations, underscoring the strong “magnetic appeal” of the Chinese market.

Amidst the prevailing trends, more pragmatic issues are coming to the fore: On the path from laboratory discoveries to industrial application of medical achievements, how can we leverage a five-pronged strategy—top-level design, financial empowerment, talent mechanisms, platform development, and equity reforms—to build a closed loop of “basic R&D – technology transfer – industrial implementation”? In the two-way exchange between Chinese innovation and international markets, how will a globalized innovation ecosystem network, integrating government, industry, academia, research, and capital, facilitate innovative diagnostics and therapeutics in China?

May 16-18, the Taihu Bay Life and Health Conference, proposed and initiated by the Wuxi Municipal People's Government, will be held in Wuxi.Multinational pharmaceutical giant AstraZeneca continues its deep engagement, co-hosting a series of major events with Wuxi on May 16, inviteExperts from the Six Major Spheres: Government, Industry, Academia, Research, Healthcare, and Investment, conduct in-depth discussions on the aforementioned hot topics, jointly deepen local cooperation, promote innovative development of clinical diagnosis and treatment in China, and ultimately contribute to the realization of the grand goal of "Healthy China 2030."

This series of events is divided into three major sections, each focusing onTranslation of Medical Achievements, International Cooperation in Life and Health, Ecosystem Resource LinkageWith these as the central themes, the event features a wide variety of activities and formats, which will be detailed individually below. We welcome you to scan the QR code in the enlarged image to register and secure your spot ahead of others.

Scan the QR code to register for the International Cooperation Forum on Life and Health

Scan the QR code to register for the Conference on Translation of Medical Research Achievements

Under the guidance of the Wuxi Municipal Health Commission, the Wuxi Municipal Science and Technology Bureau, and the Wuxi Industrial Innovation Research Institute, and hosted by the Wuxi Biopharmaceutical Industry Association, with co-organization by AstraZeneca (Wuxi) Trading Co., Ltd., Guangzhou Haibote Pharmaceutical Technology Co., Ltd., and the Wuxi International Life Science Innovation ParkThe Conference on the Translation of Medical Research Achievements will be held on the afternoon of May 16 at the Wuxi Taihu International Expo Center.

The conference centered onCardiovascular, Traditional Chinese Medicine (TCM), Metabolism, BiopharmaceuticalsIn vertical niche sectors, we provide clinical physicians with full-industry-chain services—including policy analysis, technology validation, investment and financing matchmaking, and CRO/CDMO translation—through conferences and seminars, government-industry-medical-investment negotiations, and project roadshows. Our aim is to build a collaborative innovation platform that integrates achievement demonstration, technology matchmaking, and industrial incubation.

As one of the co-organizers, AstraZeneca will also leverage its ecosystem advantages to deeply integrate resources from government, industry, academia, research institutions, healthcare providers, and investors, injecting strong resource momentum into this forum on the translation of scientific and technological achievements.

(Scroll through the images to view schedule details)

The site also features a special setup"Immersive Medical Technology Transfer Project Marketplace", centralized displayCardiovascular, Traditional Chinese MedicineResearch achievement translation projects in the field, providing clinicians with a “zero-threshold” platform for publishing their findings and facilitating deep integration between scientific research outcomes and industrial resources.

As one of the key emerging forces driving pharmaceutical innovation in China, AstraZeneca actively serves as a bridge for multinational enterprises, spanning the field of life and healthGlobal Innovation R&D, Commercialization of Technological Achievements, International Industrial Cooperation, Cross-Border Financial Investmentfacilitate two-way exchanges between Chinese innovation and international markets in these areas, thereby supporting the global development of China’s life and health industry.

In line with this strategy, the event is hosted by AstraZeneca Investment (China) Co., Ltd., and co-organized by the National Technology Innovation Center of the Yangtze River Delta, the Wuxi Biopharmaceutical Industry Association, and the Wuxi International Life Science Innovation Park.The International Forum on Life and Health Cooperation will also open at the Wuxi Taihu International Expo Center on the afternoon of May 16.。

By analyzing the full lifecycle development trajectory of products—from laboratory research and industrial commercialization to global distribution—AstraZeneca aims to collaborate with multiple stakeholders across government, industry, academia, research, and investment sectors, both domestically and internationally, to build a diversified health innovation ecosystem and jointly promote the high-quality development of China’s life and health industry.

(Scroll through the images to view schedule details)

A 108-square-meter exhibition hall for innovative achievements was specially built for this event, systematically showcasing AstraZeneca’s“Supporting innovation, transforming diagnostic and therapeutic technologies, building a healthy ecosystem, and promoting sustainable development”Four Major Pathways Supporting the Strategic Layout and Development Achievements of “Healthy China”

Furthermore, the 2025 Ecosystem Gala Dinner brought together distinguished guests from government, academia, research institutions, industry, healthcare, and investment sectors, continuously fostering a mechanism for in-depth dialogue among clinical experts, industry representatives, and investment institutions, thereby cultivating a fertile ground for cross-sector collaboration.

AstraZeneca remains firmly optimistic about the prospects of China’s economy and the innovative development of its biopharmaceutical industry. Actively responding to the Outline of the “Healthy China 2030” Plan, we continue to advance science and innovation, promote transformation in diagnosis and treatment as well as shared health, and support sustainable development. We sincerely invite partners from all sectors to actively join us in the noble endeavor of “boosting the high-quality development of China’s pharmaceutical industry and building a community of common health for mankind.”

Welcome, everyoneClick to enlarge the QR code for scanning.Register to attend. May 16, Wuxi, Jiangsu. We look forward to meeting you.

Scan the QR code to register for the International Cooperation Forum on Life and Health

Scan the QR code to register for the Conference on Translation of Medical Research Achievements

This material is provided by AstraZeneca and is intended solely for conference publicity during the Taihu Bay Life and Health Future Conference, not for product promotion purposes.

Approval No. CN-158975, Validity: 2025-07-24